Castle Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Castle Biosciences

02/11/2022 21:02

* Castle Biosciences Inc  CSTL.OQ  reported a quarterly
adjusted
loss of 77 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of 88 cents per share.
    * Revenue rose 57.7% to $37.01 million from a year ago;
analysts
expected $34.75 million. 
    * Castle Biosciences Inc's reported EPS for the quarter was
a loss
of 77 cents​.
    * The mean earnings estimate of analysts had fallen by
about 10.6%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Castle Biosciences Inc shares had fallen by 1.0% this
quarter and lost 39.8% so far this year.
    * The company reported a quarterly loss of $20.25 million.
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $48.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
2 at 09:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.88          -0.77          Beat
 Jun. 30 2022      -0.76          -0.06          Beat
 Mar. 31 2022      -0.71          -0.97          Missed
 Dec. 31 2021      -0.47          -0.25          Beat